Rapid Response From San Francisco: Management of Post-Surgical Ocular Pain and Inflammation

0.75 CME
45 MINS
$0 FEE
SAVE
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Rapid Response from San Francisco: Management of Post-Surgical Ocular Pain and Inflammation.

Overview

Provider Statement

This continuing medical education activity is provided by Vindico Medical Education.


Support Statement

This activity is supported by an educational grant from Ocular Therapeutix, Inc.


Target Audience

The intended audience for the activity is ophthalmologists and other health care professionals involved in the management of patients with post-surgical ocular pain and inflammation.


Learning Objectives

Upon successful completion of this educational activity, participants should be better able to:

  • Summarize the impact of pain and inflammation on patient outcomes following ophthalmic surgery.
  • Assess the latest clinical evidence regarding new therapeutics to reduce postoperative pain and inflammation following ophthalmic surgery.

Activity Co-Chairs

Eric D. Donnenfeld, MD
Ophthalmic Consultants of Long Island
Clinical Professor of Ophthalmology
New York University
Trustee, Dartmouth Medical School
New York, NY

John A. Hovanesian, MD, FACS
Harvard Eye Associates
Laguna Hills, CA


Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP


Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, October 29, 2019, through October 29, 2020.


How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the video, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 out of 3 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate. 


Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. 

Activity Co-Chairs report the following relationships

Eric D. Donnenfeld, MD
Consulting Fee: AcuFocus, Alcon, Allegro, Allergan, Avedro, Bausch + Lomb, BlephEx, BVI, CRST, CorneaGen, Dompe, Elenza, EyePoint Pharma, ForeSight, Glaukos, Icon Bioscience, Johnson & Johnson, Kala, Katena, LacriPen, LensGen, Mati Pharmaceuticals, MDBackline, Merck, Mimetogen, Nanowafer, NovaBay, Novaliq, Novartis, Ocular Innovations, Oculis, Odyssey, Omega Ophthalmics, Orasis, Oyster Point Therapeutics, Pfizer, PogoTec, PRN, ReTear, RPS, Shire, Strathspey Crown, Sun, Surface, TearLab, TLC Laser Centers, TrueVision, Veracity, Versant Ventures, Zeiss
Speakers Bureau: AcuFocus, Alcon, Allegro, Allergan, Avedro, Bausch + Lomb, BlephEx, BVI, CRST, CorneaGen, Dompe, Elenza, EyePoint Pharma, ForeSight, Glaukos, Icon Bioscience, Johnson & Johnson, Kala, Katena, LacriPen, LensGen, Mati Pharmaceuticals, MDBackline, Merck, Mimetogen, Nanowafer, NovaBay, Novaliq, Novartis, Ocular Innovations, Oculis, Odyssey, Omega Ophthalmics, Orasis, Oyster Point Therapeutics, Pfizer, PogoTec, PRN, ReTear, RPS, Shire, Strathspey Crown, Sun, Surface, TearLab, TLC Laser Centers, TrueVision, Veracity, Versant Ventures, Zeiss
Ownership Interest: AcuFocus, Avedro, CorneaGen, Elenza, EyePoint Pharma, Glaukos, LacriPen, LensGen, Mati Pharmaceuticals, MDBackline, Mimetogen, NovaBay, OcuHub, Ocular Innovations, Oculis, Orasis, PogoTec, ReTear, RPS, Sarcode, Strathspey Crown, Surface, TearLab, TrueVision, Veracity, Versant Ventures, Visionary Ventures

John A. Hovanesian, MD, FACS
Royalty: SLACK Incorporated, TLC Laser Eye Centers
Consulting Fee: 1-800-DOCTORS, Abbott Medical Optics, AcuFocus, Aerie, Alcon, Allegro Ophthalmics, Allergan, BlephEx, Eyedetec, Glaukos, Guardion Health Sciences, IOP/Katena, Ivantis, Kala, Novartis, Ocular Therapeutix, Omeros, ReVision Optics, Sarentis Ophthalmic, Sensimed, Shire, Tear Film Innovations, TearLab, Valeant, Varacity
Contracted Research: Abbott Medical Optics, AcuFocus, Aerie, Alcon, Allergan, Cloudbreak Therapeutics, Cord LLC, Eyedetec, Glaukos, IngenoEye, IOP/Katena, Novartis, Ocular Therapeutix, Omeros, ReVision Optics, Shire, Tear Film Innovations, Valeant
Ownership Interest: Alcon, Alicia Surgery Center, Allegro Ophthalmics, Allergan, BlephEx, Eyedetec, Glaukos, Guardion Health Sciences, Harvard Eye Associates, Harvard Hearing, IngenoEye, MDbackline, Novartis, Ocular Therapeutix, RxSight, Sarentis Ophthalmics, Sight Sciences, Tear Film Innovations
Medical Advisory Board: 1-800-DOCTORS, Abbott Medical Optics, Aerie, BlephEx, Cord LLC, Eyedetec, Glaukos, Guardion Health Sciences, IngenoEye, IOP/Katena, Ivantis, Kala, MDbackline, Ocular Therapeutix, Omeros, ReVision Optics, Shire, Sight Sciences, Tear Film Innovations, TearLab, Valeant, Veracity

Reviewer reports the following relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose. 

Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.


Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-–FDA-approved or investigational use of products/devices.


Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.


CME Questions?

Contact us at cme@vindicoCME.com